Esketamine Nasal Spray Market Size & Share, by Type (Treatment Resistant Depression, Major Depressive Disorder), End User (Inpatient Facilities, Outpatient Clinics, Specialty Clinics) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5318
  • Published Date: Oct 13, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Esketamine Nasal Spray Market size is expected to cross USD 8 billion by the end of 2036, growing at a CAGR of 7% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of esketamine nasal spray was around USD 4 billion. The market for Esketamine nasal spray is emerging and expected to grow more over the forecast period, and its availability and adoption varied from country to country. Factors such as regulatory approval, healthcare policies, and the acceptance of this novel treatment approach by the medical community influenced its market presence. Esketamine is a derivative of ketamine, a well-known anesthetic. It was developed as a novel treatment for depression, specifically for individuals with treatment-resistant depression (TRD).

Esketamine's introduction marked a significant advancement in the treatment of depression, especially for those who did not respond to traditional antidepressants. Ongoing research aimed at better understanding esketamine's long-term effects and refining its administration protocols. Efforts to expand the market to include more patient groups, such as adolescents with depression. Potential developments in generic versions of esketamine nasal spray, which could impact pricing and accessibility. Increased adoption as healthcare systems and providers gains more experience with its use. Regulatory agencies in various countries, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), granted approvals for Esketamine nasal spray. Approval in other countries followed, but the regulatory pathways and availability varied.

/admin/upload_images/Esketamine Nasal Spray Market_IG.webp
Get more information on this report: Request Free Sample PDF

Esketamine Nasal Spray Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 4 Billion

Forecast Year Market Size (2036)

~ USD 8 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)

Esketamine Nasal Spray Market: Growth Drivers and Challenges


Growth Drivers

  • Treatment-Resistant Depression Prevalence: The high prevalence of treatment-resistant depression is a primary driver for the Esketamine Nasal Spray market. Traditional antidepressants do not provide relief for a substantial segment of the depressed population. Esketamine, as a novel treatment, offers a potential solution for these individuals. It acts on a different mechanism in the brain, providing hope for patients who have been unresponsive to other treatments. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting more than 264 million people. Of this population, a significant portion does not respond to traditional antidepressant treatments.
  • Rapid Onset of Action: The rapid onset of action is a compelling driver for the Esketamine Nasal Spray market. Depression can cause immense suffering and functional impairment. Esketamine's ability to alleviate symptoms quickly addresses the pressing need for immediate relief, reducing the burden of long-lasting depressive episodes. It provides hope and a tangible solution for patients in crisis. Clinical studies have consistently demonstrated that Esketamine often produces rapid relief from depressive symptoms, with effects seen within hours or days, as opposed to the several weeks it may take for many traditional antidepressants to take effect.
  • Research and Development: Research and development efforts in the field of Esketamine ensure that the treatment continues to evolve and meet the specific needs of diverse patient groups. This not only enhances the clinical effectiveness of Esketamine but also expands its market potential. As researchers explore its applications in adolescents and individuals with concurrent conditions, the Esketamine Nasal Spray market is positioned for continued growth. Ongoing research and clinical trials have aimed to expand Esketamine's use to different patient populations, including adolescents and those with comorbid conditions.
  • Investments in Healthcare: As treatment-resistant depression remains a global concern, and mental health awareness continues to rise, Esketamine offers a solution with its rapid action and regulatory approvals. Investments in healthcare infrastructure, as well as ongoing research and development, are shaping the market's future, making it a pivotal player in the evolving landscape of mental health treatment.


  • Cost of Treatment: Esketamine treatment can be expensive, which can create financial barriers for patients. Insurance coverage and reimbursement policies vary, and not all patients may have access to the treatment due to cost concerns. This cost challenge can limit the esketamine nasal spray market growth potential, especially for individuals without adequate insurance coverage or financial resources. The cost of Esketamine itself is a notable challenge. Esketamine is a specialty medication and typically more expensive than traditional antidepressants. The high cost of the medication can be a significant barrier for patients, particularly for those without insurance coverage or with high out-of-pocket expenses. Esketamine is often administered in multiple doses over several weeks. The frequency of administration may vary based on individual patient needs
  • Administration and Monitoring Requirements
  • Side Effects and Safety Concerns

Esketamine Nasal Spray Segmentation

Type (Treatment Resistant Depression, Major Depressive Disorder)

The major depressive disorder segment in the esketamine nasal spray market is estimated to gain the largest revenue share of 61% in the year 2036. One of Esketamine's notable characteristics is its rapid onset of action. Clinical studies and trials have consistently demonstrated that this medication can lead to a notable reduction in depressive symptoms within hours or days, compared to the several weeks it often takes for traditional antidepressants to exhibit their full therapeutic effects. This rapid action can result in quicker relief and recovery, reducing the duration of debilitating depressive episodes. Esketamine's rapid onset of action serves as a compelling growth driver for the esketamine nasal spray market in the major depressive disorder segment. Depression, especially when severe, can cause immense suffering, affect work productivity, and strain personal relationships. Patients and their families are eager for effective interventions that can provide prompt relief. Esketamine's ability to alleviate symptoms more rapidly than traditional treatments addresses this pressing need, offering individuals the possibility of an earlier return to their normal lives. The growth drivers for esketamine nasal spray market in the Major Depressive Disorder (MDD) segment are deeply rooted in the urgent need to address the high prevalence of MDD, the limitations of existing therapies, the swift alleviation of symptoms, the significance of regulatory approvals, and the life-saving potential in reducing suicide risk. Esketamine provides new hope and possibilities for individuals suffering from MDD, illustrating the profound impact it can have on mental health treatment and overall quality of life.

End User (Inpatient Facilities, Outpatient Clinics, Specialty Clinics)

Esketamine nasal spray market from the inpatient facilities segment is expected to garner a significant share in the year 2036. Esketamine's notable ability to address suicidal ideation is a crucial growth driver for its use in inpatient facilities. According to the World Health Organization (WHO), depression is a leading risk factor for suicide, with MDD being a significant contributor. Individuals in inpatient facilities are often in acute crisis, facing imminent harm or the risk of self-harm. Esketamine's capacity to alleviate suicidal ideation rapidly is transformative in these high-stakes situations. World Health Organization estimates that close to 800,000 people die by suicide each year, making it a major global public health concern. Esketamine's ability to mitigate suicide risk is of paramount importance in inpatient settings, where patients require immediate and effective intervention. This growth driver has the potential to save lives, making Esketamine a crucial tool for healthcare providers in their mission to protect and care for individuals in acute psychiatric distress. The growth drivers for esketamine nasal spray market in inpatient facilities are multifaceted and deeply impactful. Esketamine's ability to address suicidal ideation, treatment-resistant depression, acute distress, and agitation, coupled with the enhanced safety measures in inpatient settings, makes it a pivotal intervention in psychiatric care. Furthermore, the potential to reduce the length of inpatient stays offers a dual benefit of improving patient outcomes while optimizing resource allocation in healthcare.

Our in-depth analysis of the global esketamine nasal spray market includes the following segments:


  • Treatment Resistant Depression
  • Major Depressive Disorder



                                                          End User

  • Inpatient Facilities
  • Outpatient Clinics
  • Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Esketamine Nasal Spray Industry - Regional Synopsis

APAC Market Forecast

The esketamine nasal spray market in the Asia Pacific region is projected to hold the largest market share of 40% by the end of 2036. The growing mental health concerns in Asia underscore the demand for effective treatments such as Esketamine Nasal Spray. Esketamine offers a novel approach to addressing treatment-resistant depression, providing hope for individuals who may have previously struggled to find appropriate treatment. The Asia Pacific Mental Health Integration Index reports that mental health issues are on the rise in the region, with approximately 44% of the global burden of mental health disorders occurring in Asia. Mental health concerns are on the rise across the Asia Pacific region. In many Asian countries, there has been a shift in societal attitudes, with increasing awareness and a reduction in stigma surrounding mental health issues. With economic and societal changes, urbanization, and changing lifestyles, the Asia Pacific region in the esketamine nasal spray market is experiencing a higher prevalence of mental health disorders, including depression.

North American Market Statistics

The esketamine nasal spray market in the North America region is projected to hold the second largest share during the forecast period.  Regulatory approvals are instrumental in establishing the legitimacy of Esketamine as an effective treatment. In North America, Esketamine has received approvals from the United States Food and Drug Administration (FDA) and Health Canada for the treatment of Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD). Esketamine received FDA approval for TRD in 2019 and subsequently for MDD in 2020, following clinical trials demonstrating its efficacy and safety. Regulatory approvals signify that Esketamine has met stringent standards for safety and efficacy, providing healthcare providers and patients with confidence in its use. They are pivotal in Esketamine's journey to becoming a mainstream treatment option for depression in North America. Esketamine is renowned for its rapid onset of action, offering a compelling alternative to traditional antidepressants that may take weeks to show significant effects. This rapid action can be life-changing for individuals experiencing acute and severe depressive symptoms. Clinical trials have consistently shown that Esketamine can lead to a noticeable reduction in depressive symptoms within hours, compared to several weeks with traditional antidepressants.

Research Nester
/admin/upload_images/Esketamine Nasal Spray Market_IG size.webp
Get more information on this report: Request Free Sample PDF

Companies Dominating the Esketamine Nasal Spray Market

    • Janssen Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Otsuka Pharmaceutical Co., Ltd.
    • Allergan, Inc.
    • H. Lundbeck A/S
    • Johnson & Johnson
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Valeant Pharmaceuticals International, Inc.
    • Hikma Pharmaceuticals PLC


In The News

  • In 2019, Otsuka Pharmaceutical acquired AveXis, a US-based biotechnology company that develops gene therapies for rare genetic diseases, for USD 8.3 billion.
  • In 2021, Otsuka Pharmaceutical merged its wholly owned subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc., a US-based pharmaceutical company, with Otsuka Pharmaceutical America, Inc., a US-based pharmaceutical company.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5318
  • Published Date: Oct 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for oil and gas is the major factor driving the market growth.

The market size of esketamine nasal spray is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Janssen Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Allergan, Inc. (now part of AbbVie), H. Lundbeck A/S, Johnson & Johnson, Mylan N.V., and others.

The inpatient facilities segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Esketamine Nasal Spray Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying